Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.
about
NLRX1 negatively modulates type I IFN to facilitate KSHV reactivation from latency.Role of Natural Killer Cells in HIV-Associated Malignancies.Diagnosis and Treatment of Kaposi Sarcoma.Primary lymphocyte infection models for KSHV and its putative tumorigenesis mechanisms in B cell lymphomas.Multiple viral infections in primary effusion lymphoma: a model of viral cooperation in lymphomagenesis.Deregulation of KSHV latency conformation by ER-stress and caspase-dependent RAD21-cleavage.Microbiota dysbiosis in select human cancers: Evidence of association and causality.Oral shedding of herpesviruses in HIV-infected patients with varying degrees of immune status.Kaposi's Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes.The Roles of Matricellular Proteins in Oncogenic Virus-Induced Cancers and Their Potential Utilities as Therapeutic Targets.Viral Oncology: Molecular Biology and Pathogenesis.Toe web intertrigo in Kaposi's sarcoma patients: a microbiological study in a large cohort of patients.Kaposi's Sarcoma-Associated Herpesvirus: Epidemiology and Molecular Biology.Pediatric Kaposi sarcoma in context of the HIV epidemic in sub-Saharan Africa: current perspectives.Synergistic Viral Replication of Marek's Disease Virus and Avian Leukosis Virus Subgroup J is Responsible for the Enhanced Pathogenicity in the Superinfection of Chickens.The Immunomodulatory Capacity of an Epstein-Barr Virus Abortive Lytic Cycle: Potential Contribution to Viral Tumorigenesis.Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.Role of Pattern Recognition Receptors in KSHV Infection.Kaposi sarcoma-associated herpesvirus latency locus renders B cells hyperresponsive to secondary infectionsCoinfections and comorbidities in African health systems: At the interface of infectious and noninfectious diseasesChromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latencyKaposi's sarcoma in an HIV-negative chronic lymphocytic leukemia patient without immunosuppressive therapy: A case report
P2860
Q36359794-90F7D012-DD5C-4F09-A3F5-64A2776E757CQ37712593-C6D11923-1297-47E2-99CD-4EB3D167AF22Q39190555-456D76E8-975B-4F3B-A165-3C28235492E9Q39271443-D98B2EEC-2C2A-4F3B-AAFB-8A15CBEE066DQ39281253-E997F028-427B-4E1D-A67F-77B2D5812C07Q40064939-B0FE3113-D004-4328-A126-D02736EA8783Q40077721-203F3AD4-BA3F-476D-A529-EDD20D1ABE69Q40116637-7FCF730D-0984-43E9-8302-616294814C1AQ41919772-66A45C32-A9A9-46A9-AD37-B8A4E925A5AEQ45325755-A86291A0-78A5-44A0-9EC7-7C51836528C6Q47571734-5F964A3D-1F7E-4CE6-832D-875287F982A3Q47576219-FAE06778-34A9-4649-B98D-FD2BD8E2FE5BQ47606321-EB33897C-E860-47F5-8893-44B925198857Q53686620-E681E3CA-B5DE-45C0-8C85-7F64D54C16E2Q54204054-ADB4715F-89AF-420C-B011-CEF41A85D4FFQ54245037-9146A22D-59BF-4CDE-836C-8F81A7E08B8FQ55085319-20B83EDC-0ED6-4C7B-9620-DBF4D589F0E0Q55338587-83B386F2-3D30-4BA0-93B6-772191AC1320Q56345322-7FE2C635-686B-4542-B3FB-44EA1620BEDBQ58713842-D6ACBB51-EC23-4F25-998D-EF2B818E62F1Q58744047-6C846290-6499-43F7-B9ED-7869CD638382Q58756174-0DAAA79B-8F01-484D-86C5-2B9DE9548B6A
P2860
Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.
@en
type
label
Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.
@en
prefLabel
Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.
@en
P2860
P356
P1476
Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.
@en
P2093
Dirk P Dittmer
P2860
P304
P356
10.1172/JCI84418
P407
P577
2016-09-01T00:00:00Z